Dexlansoprazole is a proton pump inhibitor used to treat erosive esophagitis, heartburn, and gastroesophageal reflux disease (GERD). Dexlansoprazole is the R-enantiomer of DB00448, which is composed of a racemic mixture of the R- and S-enantiomers.
- Mechanism
- Curator reviewed · 2 references
Dexlansoprazole suppresses gastric acid secretion by blocking the final step of acid production. It inhibits the H/K ATPase at the secretory surface of the gastric parietal cell, which is involved in the secretion of hydrochloric acid. H/K ATPase is a proton pump responsible for hydrolyzing ATP and exchanging H+ ions from the cytoplasm for K+ ions in the secretory canaliculus: this action results in hydrochloric acid secretion into the gastric lumen.
- Primary indication
- Dexlansoprazole is a proton pump inhibitor (PPI) indicated for the: Healing of all grades of erosive esophagitis (EE) for up to eight weeks in patients 12 years of age and older. - Maintenance of healed...Curator reviewed · 6 structured indications
- Formula / weight
- C16H14F3N3O2S · 369.36 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2009
- Also known as
- (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE · (R)-LANSOPRAZOLE · 1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)- · LANSOPRAZOLE R-FORM · LANSOPRAZOLE, (R)-
- Code names
- NSC-758710 · T-168390 · TAK-390 · TAK-390MR
- Brand names
Resolves to
MJIHNNLFOKEZEW-RUZDIDTESA-NSMILESCC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Dexlansoprazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account